Dr. Gomperts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street Wac 830
Massachusetts General Hospital
Boston, MA 02114Phone+1 617-726-1728Fax+1 617-726-4101
Summary
- Dr. Stephen Gomperts is a neurologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from University of California San Francisco School of Medicine and has been in practice 16 years. He specializes in Movement Disorders and Dementia & is the founding Director of the MGH Lewy Body Dementia Unit.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 2001 - 2002
University of California San Francisco School of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2005 - 2026
RI State Medical License 2021 - 2026
NH State Medical License 2021 - 2025
ME State Medical License 2021 - 2024- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 1957 citationsDiagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB ConsortiumIan G. McKeith, Bradley F. Boeve, Dennis W. Dickson, Glenda M. Halliday, John-Paul Taylor
Neurology. 2017-07-04 - 112 citationsPostsynaptically silent synapses in single neuron culturesStephen N. Gomperts, Anuradha Rao, Ann Marie Craig, Robert C. Malenka, Roger A. Nicoll
Neuron. 1998-12-01 - 480 citationsValidating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissueMarta Marquié, Marc D. Normandin, Charles R. Vanderburg, Isabel Costantino, Elizabeth Bien
Annals of Neurology. 2015-11-01
Press Mentions
Cigarette Carbon Monoxide May Protect Against Parkinson'sSeptember 9th, 2024- EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer's Disease (CTAD) MeetingNovember 7th, 2020
- EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy Bodies (DLB)October 6th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
